Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
AssigneeBayer Aktiengesellschaft
InventorsKris P. Antonsen, Rajiv Nayar, Wei Wang, Margaret Caudle, Michael A. Shearer, Neville M. Concessio
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions for delivery of drugs intended to reside in the nose, compositions for nasal administration of drugs, e.g., antiviral agents, and particularly antiviral agents comprising the human major rhinovirus receptor, also known as intercellular adhesion molecule-1 (ICAM-1); to methods of making said nasal drug compositions, and to an improved process for the removal of residual solvent from pharmaceutical matrices.
Claims25
A process for making an intranasal drug delivery system comprising gelatin microspheres in combination with a drug intended for intranasal delivery, said process comprising:
- a) preparing a low-salt or salt-free aqueous solution of gelatin and the drug to be delivered, at a temperature above the gelation temperature of the gelatin;
- b) preparing a solution of a suitable oil and a suitable surfactant;
- c) emulsifying a mixture of the solution of step (a) and the solution of step (b) to generate a water-in-oil emulsion wherein the volume ratio of (a):(b) is between 1:2 and 1:10;
- d) continuing emulsification until the target droplet size is achieved;
- e) reducing the temperature of said emulsion to below the gelation temperature of the gelatin at a controlled rapid rate to achieve gelation before droplet coalescence, thus allowing the formation of gelatin microspheres associated with drug at the desired particle size;
- the emulsion in steps (c, d) and (e) above being mixed at the maximum rate consistent with a low-vortex or vortex-free circulation pattern;
- f) separating the drug-containing microspheres from the oil/surfactant phase;
- and
- g) dehydrating the drug-containing microspheres to produce a dry powder.
A process for removing residual solvent from a pharmaceutical matrix, comprising contacting said pharmaceutical matrix with a humidified gas under conditions which permit residual solvent to be entrained in the gas, and removing the gas.
Dependencies are inferred from the claim text.